Vicente Corrales-Medina, Jordana B. Cohen, Seavmeiyin Kun, Bianca Pourmussa, Ozgun Erten, Joe-David Azzo, Julio A. Chirinos
{"title":"Short report: Hospitalization for new-onset heart failure in survivors of hospitalized COVID-19","authors":"Vicente Corrales-Medina, Jordana B. Cohen, Seavmeiyin Kun, Bianca Pourmussa, Ozgun Erten, Joe-David Azzo, Julio A. Chirinos","doi":"10.1002/ehf2.15331","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Previous studies have reported an incidence of new-onset heart failure (HF) among COVID-19 survivors ranging from 0.7 to 8.5 per 100 person-years, but they relied on administrative data for outcome ascertainment. Given the public health implications, a more accurate characterization of the HF burden post-COVID-19 is important.</p>\n </section>\n \n <section>\n \n <h3> Methods and results</h3>\n \n <p>We conducted a prospective cohort study of survivors of hospitalized COVID-19 and tracked the incidence of new-onset HF hospitalizations over the 12-month period following the index COVID-19 episode. Outcome ascertainment was based on a combination of chart reviews, patient interviews, and pre-specified clinical, radiographic and laboratory criteria. We identified 2140 survivors of COVID-19 hospitalization that were free of HF at the time of discharge. Their mean age was 67 years and 48% were Black/African-Americans. The incidence rate of hospitalized new-onset HF was 0.5 per 100 person-years. Higher BMI and dialysis dependency at baseline were significantly associated with HF development. The 1-year mortality rate was 3%.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The incidence of new-onset HF post-COVID-19 in our study was lower than in previous reports, despite involving an older population with more comorbidities and/or more severe COVID-19 overall. Reliance on administrative data for outcome adjudication in prior studies may have led to an overestimation of the HF burden post-COVID-19.</p>\n </section>\n </div>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":"12 4","pages":"3073-3078"},"PeriodicalIF":3.7000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ehf2.15331","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15331","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aims
Previous studies have reported an incidence of new-onset heart failure (HF) among COVID-19 survivors ranging from 0.7 to 8.5 per 100 person-years, but they relied on administrative data for outcome ascertainment. Given the public health implications, a more accurate characterization of the HF burden post-COVID-19 is important.
Methods and results
We conducted a prospective cohort study of survivors of hospitalized COVID-19 and tracked the incidence of new-onset HF hospitalizations over the 12-month period following the index COVID-19 episode. Outcome ascertainment was based on a combination of chart reviews, patient interviews, and pre-specified clinical, radiographic and laboratory criteria. We identified 2140 survivors of COVID-19 hospitalization that were free of HF at the time of discharge. Their mean age was 67 years and 48% were Black/African-Americans. The incidence rate of hospitalized new-onset HF was 0.5 per 100 person-years. Higher BMI and dialysis dependency at baseline were significantly associated with HF development. The 1-year mortality rate was 3%.
Conclusions
The incidence of new-onset HF post-COVID-19 in our study was lower than in previous reports, despite involving an older population with more comorbidities and/or more severe COVID-19 overall. Reliance on administrative data for outcome adjudication in prior studies may have led to an overestimation of the HF burden post-COVID-19.
期刊介绍:
ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.